Among 24 HER2+ breast cancer patients, 14 patients received standard NAC and of them, 7 patients attained complete pathological response (pCR) while pCR data was unavailable for 2 patients and remaining 5 patients had residual tumor with RCBI I or II. The gene discussed is ERBB2; the disease is breast cancer.